Abbott Laboratories (ETR:ABL)
Germany · Delayed Price · Currency is EUR | Market Cap | 189.75B |
| Revenue (ttm) | 37.37B |
| Net Income (ttm) | 11.87B |
| Shares Out | n/a |
| EPS (ttm) | 6.78 |
| PE Ratio | 15.99 |
| Forward PE | 22.58 |
| Dividend | 2.11 (1.93%) |
| Ex-Dividend Date | Oct 15, 2025 |
| Volume | 785 |
| Average Volume | 618 |
| Open | 108.02 |
| Previous Close | 107.42 |
| Day's Range | 108.02 - 109.02 |
| 52-Week Range | 104.08 - 134.14 |
| Beta | 0.70 |
| RSI | 46.43 |
| Earnings Date | Jan 22, 2026 |
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism,... [Read more]
Financial Performance
In 2024, Abbott Laboratories's revenue was $41.95 billion, an increase of 4.59% compared to the previous year's $40.11 billion. Earnings were $13.35 billion, an increase of 134.19%.
Financial numbers in USD Financial StatementsNews
10 Defensive Stocks with Market-Beating Yields
It's been a great year for stocks, but in the past few days the bull market seems to have lost some of its mojo.
Christine Poole's Top Picks: Abbott Labs, CN Rail & Otis Worldwide
Christine Poole, co-chief investment officer at Davis Rea, shares her top stock picks to watch in the market.
Best Dividend Aristocrats For November 2025
The ProShares S&P 500 Dividend Aristocrats ETF (NOBL) has underperformed SPY in 2025, with a 6.27% YTD gain versus SPY's 17.8%. Despite overall underperformance, select Aristocrats like CAT, CAH, CHRW...
Abbott Showcases World's First Dual Chamber Leadless Pacemaker in National Media Tour Featuring Patient Story with YourUpdateTV
Boston Teacher Shares Life-Changing Experience with Breakthrough Dual Chamber Leadless Pacemaker During Nationwide Interviews in Conjunction with D S Simon Media Boston Teacher Shares Life-Changing Ex...
Best Dividend Kings: October 2025
Dividend Kings are underperforming SPY in 2025, with a year-to-date return gap of 13.10%, but 12 Kings remain ahead of the index. Top performers include NFG, JNJ, ABBV, MO, FTS, ADM, NUE, GRC, NWN, PH...
Is the Market Bullish or Bearish on Abbott Laboratories?
Abbott Laboratories's (NYSE: ABT) short interest as a percent of float has risen 6.67% since its last report. According to exchange reported data, there are now 19.36 million shares sold short , whic...
A Look Into Abbott Laboratories Inc's Price Over Earnings
In the current market session, Abbott Laboratories Inc. (NYSE: ABT) share price is at $128.64, after a 0.86% increase. Moreover, over the past month, the stock fell by 3.92% , but in the past year, i...
Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock
Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Walmart to be first US retailer to sell Abbott's continuous glucose monitor, Axios reports
Walmart will become the first U.S. retailer to sell an over-the-counter continuous glucose monitor in physical stores, as Abbott Laboratories' Lingo rolls out to more than 3,500 locations and online, ...
Abbott: GLP-1 Beneficiary - A Dividend Raise May Be Coming
The market has overreacted to ABT's lowered FY2025 organic sales growth/narrowed adj. EPS, since the management continues to deliver robust numbers while building upon FY2024 outperformance. Much of i...
Peter Lynch Detailed Fundamental Analysis - ABT
Below is Validea's guru fundamental report for ABBOTT LABORATORIES (ABT). Of the 22 guru strategies we follow, ABT rates highest using our P/E/Growth Investor model based on the published strategy of ...
S&P 500 Analyst Moves: ABT
The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Abbott Laboratories is now the #85 analyst pick, moving up by 1 spot. This ra...
Analyst Sees Noise In Q3 P&L, Affirms Abbott's Medtech Strength
Abbott Laboratories (NYSE: ABT) reported muted sales in the third quarter on Wednesday and narrowed its fiscal 2025 guidance . The company reported third-quarter sales of $11.37 billion, slightly mis...
These Analysts Revise Their Forecasts On Abbott Following Q3 Results
Abbott Laboratories (NYSE: ABT) reported muted sales in the third quarter and narrowed fiscal 2025 guidance on Wednesday. The company reported third-quarter sales of $11.37 billion, slightly missing ...
These Analysts Revise Their Forecasts On Abbott Following Q3 Results
Abbott Laboratories (NYSE:ABT) reported muted sales in the third quarter and narrowed fiscal 2025 guidance on Wednesday.
Wells Fargo Raises Abbott Laboratories (ABT) Price Target to $146 | ABT Stock News
Wells Fargo Raises Abbott Laboratories (ABT) Price Target to $146 | ABT Stock News
Abbott Laboratories Q3 2025 Earnings: Stable Growth Amid Tariff And China Headwinds
Salesforce mit neuen Plänen, TSMC stark, Morgan Stanley toppt Erwartungen • news
FlatexDeGiro, Sartorius, Abbott Laboratories, Bank of America, Morgan Stanley, United Airlines, Apple, Nvidia, Arm, Hims & Hers, Salesforce, Taiwan Semi.
Abbott Laboratories (ABT) Q3 2025 Earnings Call Highlights: Strong Organic Growth and Medical ...
Abbott Laboratories (ABT) Q3 2025 Earnings Call Highlights: Strong Organic Growth and Medical Devices Lead the Way
Abbott Laboratories (ABT) Sees Robust Growth in Q3 2025
Abbott Laboratories (ABT) Sees Robust Growth in Q3 2025
Gold Gains Over 1%; Abbott Shares Fall After Q3 Results
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 100 points on Wednesday. The Dow traded up 0.06% to 46,299.96 while the NASDAQ climbed 0.52% to 22,639....
Gold Gains Over 1%; Abbott Shares Fall After Q3 Results
Abbott Laboratories (NYSE:ABT) stock fell around 2.6% on Wednesday after the company reported muted sales in the third quarter and narrowed fiscal 2025 guidance.
Q3 2025 Abbott Laboratories Earnings Call Transcript
Q3 2025 Abbott Laboratories Earnings Call Transcript
Abbott Laboratories (ABT) Q3 2025 Earnings Call Transcript
Abbott Laboratories' Q3 2025 Results: Steady Performance with Limited Upside
Abbott Laboratories' Q3 2025 Results: Steady Performance with Limited Upside